ATAI Life Sciences (Drug Discovery) Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Public

  • Employees
  • 54

Employees

  • Stock Symbol
  • ATAI

Stock Symbol

  • Investments
  • 25

  • Share Price
  • $2.62
  • (As of Friday Closing)

ATAI Life Sciences (Drug Discovery) General Information

Description

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.

Contact Information

Website
www.atai.com
Formerly Known As
ATAI Lifesciences
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Wallstrasse 16
  • 10179 Berlin
  • Germany
+49 089
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • Wallstrasse 16
  • 10179 Berlin
  • Germany
+49 089

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ATAI Life Sciences (Drug Discovery) Stock Performance

As of 11-Jul-2025, ATAI Life Sciences (Drug Discovery)’s stock price is $2.62. Its current market cap is $579M with 212M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.62 $2.73 $1.03 - $2.98 $579M 212M 3.36M -$0.91

ATAI Life Sciences (Drug Discovery) Financials Summary

As of 31-Mar-2025, ATAI Life Sciences (Drug Discovery) has a trailing 12-month revenue of $1.87M.

In Thousands,
USD
TTM 31-Mar-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 232,330 161,660 43,986 158,853
Revenue 1,868 308 314 233
EBITDA (145,747) (145,586) (38,158) (134,639)
Net Income (148,987) (149,269) (40,224) (152,385)
Total Assets 195,783 159,387 293,478 305,441
Total Debt 26,668 24,706 19,142 15,341
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ATAI Life Sciences (Drug Discovery) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ATAI Life Sciences (Drug Discovery)‘s full profile, request access.

Request a free trial

ATAI Life Sciences (Drug Discovery) Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health trea
Drug Discovery
Berlin, Germany
54 As of 2024

New York, NY
 

Dublin, Ireland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ATAI Life Sciences (Drug Discovery) Competitors (12)

One of ATAI Life Sciences (Drug Discovery)’s 12 competitors is Axsome Therapeutics, a Corporation company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Axsome Therapeutics Corporation New York, NY
GH Research Formerly VC-backed Dublin, Ireland
Intracellular Therapies Formerly VC-backed Bedminster, NJ
BioXcel Therapeutics Formerly VC-backed New Haven, CT
Vistagen Therapeutics Corporation South San Francisco, CA
You’re viewing 5 of 12 competitors. Get the full list »

ATAI Life Sciences (Drug Discovery) Patents

ATAI Life Sciences (Drug Discovery) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240408054-A1 Compositions and methods for increasing exposure of r(-)-mda Pending 09-Jun-2023
US-20240425470-A1 Substituted benzofuran propyl amine modulators of monoaminergic transporters Pending 09-Jun-2023
US-20240116896-A1 Heteroatom substituted cyclic and alkyl amines as activators of serotonin receptors Pending 06-Sep-2022
US-20230270714-A1 Salvinorin compositions Inactive 08-Dec-2021
EP-4408412-A1 Compositions and methods for treating headaches Pending 30-Sep-2021 A61K31/4045
To view ATAI Life Sciences (Drug Discovery)’s complete patent history, request access »

ATAI Life Sciences (Drug Discovery) Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ATAI Life Sciences (Drug Discovery) Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ATAI Life Sciences (Drug Discovery)‘s full profile, request access.

Request a free trial

ATAI Life Sciences (Drug Discovery) Investments & Acquisitions (25)

ATAI Life Sciences (Drug Discovery)’s most recent deal was a Merger/Acquisition with Beckley Psytech for . The deal was made on 03-Jun-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Beckley Psytech 03-Jun-2025 Merger/Acquisition Drug Discovery
Psilera (N,N-Dimethyltryptamine Patent Portfolio) 20-Feb-2025 Corporate Asset Purchase Buildings and Property
Intelgenx Technologies 02-Oct-2024 Merger/Acquisition Drug Delivery
Beckley Psytech 03-Jan-2024 Later Stage VC Drug Discovery
Intelgenx Technologies 05-Dec-2023 PIPE Drug Delivery
You’re viewing 5 of 25 investments and acquisitions. Get the full list »

ATAI Life Sciences (Drug Discovery) ESG

Risk Overview

Risk Rating

Updated April, 11, 2024

33.41 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 16,048

Rank

Percentile

Pharmaceuticals

Industry

of 914

Rank

Percentile

Pharmaceuticals

Subindustry

of 451

Rank

Percentile

To view ATAI Life Sciences (Drug Discovery)’s complete esg history, request access »

ATAI Life Sciences (Drug Discovery) Exits (4)

ATAI Life Sciences (Drug Discovery)’s most recent exit was on 17-Feb-2021 from PsyProtix. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
PsyProtix 17-Feb-2021 Completed
  • 2 buyers
COMPASS Pathways 17-Apr-2020 Completed
  • 21 buyers
COMPASS Pathways 20-Sep-2018 Completed
  • 5 buyers
COMPASS Pathways Later Stage VC Completed
To view ATAI Life Sciences (Drug Discovery)’s complete exits history, request access »

ATAI Life Sciences (Drug Discovery) Affiliates

Subsidiaries (6)

Name Industry Location Year Founded
Atai Life Sciences Uk London, United Kingdom 2021
Psyber New York, NY 2020
Beckley Psytech Oxford, United Kingdom 2018
Recognify Life Sciences Berlin, Germany 2018
Intelgenx Technologies Saint-Laurent, Canada 2003
You’re viewing 5 of 6 affiliates. Get the full list.  »

ATAI Life Sciences (Drug Discovery) FAQs

  • When was ATAI Life Sciences (Drug Discovery) founded?

    ATAI Life Sciences (Drug Discovery) was founded in 2018.

  • Where is ATAI Life Sciences (Drug Discovery) headquartered?

    ATAI Life Sciences (Drug Discovery) is headquartered in Berlin, Germany.

  • What is the size of ATAI Life Sciences (Drug Discovery)?

    ATAI Life Sciences (Drug Discovery) has 54 total employees.

  • What industry is ATAI Life Sciences (Drug Discovery) in?

    ATAI Life Sciences (Drug Discovery)’s primary industry is Drug Discovery.

  • Is ATAI Life Sciences (Drug Discovery) a private or public company?

    ATAI Life Sciences (Drug Discovery) is a Public company.

  • What is ATAI Life Sciences (Drug Discovery)’s stock symbol?

    The ticker symbol for ATAI Life Sciences (Drug Discovery) is ATAI.

  • What is the current stock price of ATAI Life Sciences (Drug Discovery)?

    As of 11-Jul-2025 the stock price of ATAI Life Sciences (Drug Discovery) is $2.62.

  • What is the current market cap of ATAI Life Sciences (Drug Discovery)?

    The current market capitalization of ATAI Life Sciences (Drug Discovery) is $579M.

  • What is ATAI Life Sciences (Drug Discovery)’s current revenue?

    The trailing twelve month revenue for ATAI Life Sciences (Drug Discovery) is $1.87M.

  • Who are ATAI Life Sciences (Drug Discovery)’s competitors?

    Axsome Therapeutics, GH Research, Intracellular Therapies, BioXcel Therapeutics, and Vistagen Therapeutics are some of the 12 competitors of ATAI Life Sciences (Drug Discovery).

  • What is ATAI Life Sciences (Drug Discovery)’s annual earnings per share (EPS)?

    ATAI Life Sciences (Drug Discovery)’s EPS for 12 months was -$0.91.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »